Denavir Patent Expiration

Denavir is a drug owned by Mylan Pharmaceuticals Inc. It is protected by 6 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 17, 2020. Details of Denavir's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6579981 Antiviral guanine derivatives
Jun, 2020

(4 years ago)

Expired
US6469015 Pharmaceutical formulation
Oct, 2019

(5 years ago)

Expired
US5916893 Treatment of a latent infection of herpes virus
Sep, 2015

(9 years ago)

Expired
US5840763 Treatment of a latent infection of herpes viruses
Sep, 2015

(9 years ago)

Expired
US6124304 Penciclovir for the treatment of zoster associated pain
Oct, 2014

(10 years ago)

Expired
US5866581 Penciclovir for the treatment of post therapeutic neuralgia
Oct, 2014

(10 years ago)

Expired


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Denavir and ongoing litigations to help you estimate the early arrival of Denavir generic.

Denavir's Litigations

Denavir been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 14, 2000, against patent number US6579981. The petitioner , challenged the validity of this patent, with JARVEST et al as the respondent. Click below to track the latest information on how companies are challenging Denavir's patents.

Last updated on December 3, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6579981 January, 2000 Decision
(26 Sep, 2002)
JARVEST et al
US6579981 January, 2000 Decision
(04 Jul, 1776)
JARVEST et al

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Denavir is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Denavir's family patents as well as insights into ongoing legal events on those patents.

Denavir's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Denavir's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 17, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Denavir Generic API suppliers:

Penciclovir is the generic name for the brand Denavir. 3 different companies have already filed for the generic of Denavir, with Padagis Israel having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Denavir's generic





About Denavir

Denavir is a drug owned by Mylan Pharmaceuticals Inc. It is used for treating recurrent herpes labialis (cold sores) in adults. Denavir uses Penciclovir as an active ingredient. Denavir was launched by Mylan in 1996.

Approval Date:

Denavir was approved by FDA for market use on 24 September, 1996.

Active Ingredient:

Denavir uses Penciclovir as the active ingredient. Check out other Drugs and Companies using Penciclovir ingredient

Treatment:

Denavir is used for treating recurrent herpes labialis (cold sores) in adults.

Dosage:

Denavir is available in cream form for topical use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
1% CREAM Prescription TOPICAL